Singapore markets closed

LLY Sep 2024 930.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
33.000.00 (0.00%)
As of 01:14PM EDT. Market open.
Full screen
Loading interactive chart…
  • Yahoo Finance Video

    June consumer sentiment disappoints, Tesla short-selling: Catalysts

    On today's episode of Catalysts, co-hosts Seana Smith and Madison Mills dissect key economic data, the latest developments surrounding Tesla (TSLA), and check in on some of the day's top trending stocks. Kicking off the hour, the June Consumer Sentiment report fell to its lowest level since November, raising concerns about the economic landscape. To shed light on the market implications, Research Affiliates Founder and Chairman Rob Arnott joins to discussion, sharing his perspective on the market outlook after a hefty week of data. The show then shifts to the stock reactions of prominent companies such as Boeing (BA), GameStop (GME), and automaker Stellantis (STLA). Notably, Stellantis' decision to minimize electric vehicle production in China is explored. Finally, Tesla takes center stage with a focus on Elon Musk's recently approved $56 billion pay package. Canaccord Genuity Managing Director George Gianarikas joins the discussion, providing insights into the implications of this historic compensation plan for the company's future. Bireme Capital Founder and Chief Investment Officer Evan Tindell offers his perspective on the potential concerns surrounding short-sellers and their impact on Tesla's stock performance. This post was written by Angel Smith

  • Yahoo Finance Video

    Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market

    GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter joins Catalysts to discuss the state of the weight-loss market and the potential headwinds for these pharmaceutical companies. "There's been a duopoly situation via Lilly and Novo," Richter explains. She points to Zealand (ZEAL.CO), Amgen (AMGN), and Regeneron (REGN) as companies she's watching that could become competitors in the weight-loss market. She notes that Eli Lilly and Novo Nordisk are facing limited supply as demand skyrockets. The two pharmaceutical companies have to make significant investments to expand manufacturing capabilities, and Richter explains, "I think what everybody realizes is based on the opportunity, the investment in manufacturing and supply has to come in much earlier than perhaps thought before." For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl

  • Zacks

    Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)

    If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.